Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology
Innovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology
Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients
 with cervical cancer compared to the early detection of minimal metastatic disease.
Quantification and follow-up of circulating tumoral DNA in serum and/or plasma of patients
 with cervical cancer compared to the early detection of minimal metastatic disease.
Inclusion Criteria:

 1. Patient with cervical cancer, at any stage, before any anti-tumoral treatment.

 2. Age ≥ 18 years.

 3. Patient information and signature of the informed consent or her/his legal
 representative.

 4. Patient having given her/his agreement for a second biopsy at diagnosis if the first
 one was performed outside of the center and was not cryopreserved.

 Exclusion Criteria:

 1. Person deprived of liberty or under supervision.

 2. Inability to attend scheduled follow-up visits for any psychological, sociological or
 geographical reasons.